BACKGROUND: Large-scale randomized clinical trials are needed to assess the role of Roux-en-Y gastric bypass (RYGB) in treating patients with type 2 diabetes mellitus (T2DM). Recruitment challenges must be understood. METHODS:One hundred twenty participants were needed for a prospective randomized controlled trial investigating treatments for hyperglycemia and cardiovascular disease risk factors in patients with T2DM. The trial had two arms-intensive medical management plus a rigorous lifestyle intervention (LS/IMM) versus LS/IMM with RYGB. Medical inclusion criteria included glycosylated hemoglobin (HbA1c) ≥ 8.0 % while under the care of a physician and body mass index (BMI) 30.0-39.9 kg/m(2). Another inclusion criterion was expressed willingness to accept randomization and participate fully. Varied recruitment strategies were employed at four academic hospitals in the USA and Taiwan, including referrals, mass media, direct mail to patients drawn from a practice-based database, and direct mail to commercial mailing lists. RESULTS:Between February 2008 and December 2011, 2,648 candidates were phone-screened and 240 were screened on site; 120 participants were eventually randomized. Impediments included stringent medical inclusion criteria and a lack of equipoise (i.e., strong beliefs or preferences) among patients and their personal community-based physicians. To meet timeline requirements, the upper limit for BMI was increased from 34.9 to 39.9 kg/m(2) and an additional site was added. CONCLUSIONS: We successfully recruited 120 participants with poorly controlled T2DM and mild to moderate obesity. Participants had to be willing to accept randomization to either surgical or nonsurgical treatments. Recruitment took 4 years.
RCT Entities:
BACKGROUND: Large-scale randomized clinical trials are needed to assess the role of Roux-en-Y gastric bypass (RYGB) in treating patients with type 2 diabetes mellitus (T2DM). Recruitment challenges must be understood. METHODS: One hundred twenty participants were needed for a prospective randomized controlled trial investigating treatments for hyperglycemia and cardiovascular disease risk factors in patients with T2DM. The trial had two arms-intensive medical management plus a rigorous lifestyle intervention (LS/IMM) versus LS/IMM with RYGB. Medical inclusion criteria included glycosylated hemoglobin (HbA1c) ≥ 8.0 % while under the care of a physician and body mass index (BMI) 30.0-39.9 kg/m(2). Another inclusion criterion was expressed willingness to accept randomization and participate fully. Varied recruitment strategies were employed at four academic hospitals in the USA and Taiwan, including referrals, mass media, direct mail to patients drawn from a practice-based database, and direct mail to commercial mailing lists. RESULTS: Between February 2008 and December 2011, 2,648 candidates were phone-screened and 240 were screened on site; 120 participants were eventually randomized. Impediments included stringent medical inclusion criteria and a lack of equipoise (i.e., strong beliefs or preferences) among patients and their personal community-based physicians. To meet timeline requirements, the upper limit for BMI was increased from 34.9 to 39.9 kg/m(2) and an additional site was added. CONCLUSIONS: We successfully recruited 120 participants with poorly controlled T2DM and mild to moderate obesity. Participants had to be willing to accept randomization to either surgical or nonsurgical treatments. Recruitment took 4 years.
Authors: Geltrude Mingrone; Simona Panunzi; Andrea De Gaetano; Caterina Guidone; Amerigo Iaconelli; Laura Leccesi; Giuseppe Nanni; Alfons Pomp; Marco Castagneto; Giovanni Ghirlanda; Francesco Rubino Journal: N Engl J Med Date: 2012-03-26 Impact factor: 91.245
Authors: Donna H Ryan; Mark A Espeland; Gary D Foster; Steven M Haffner; Van S Hubbard; Karen C Johnson; Steven E Kahn; William C Knowler; Susan Z Yanovski Journal: Control Clin Trials Date: 2003-10
Authors: Sayeed Ikramuddin; Judith Korner; Wei-Jei Lee; John E Connett; William B Inabnet; Charles J Billington; Avis J Thomas; Daniel B Leslie; Keong Chong; Robert W Jeffery; Leaque Ahmed; Adrian Vella; Lee-Ming Chuang; Marc Bessler; Michael G Sarr; James M Swain; Patricia Laqua; Michael D Jensen; John P Bantle Journal: JAMA Date: 2013-06-05 Impact factor: 56.272
Authors: Nancy S Sung; William F Crowley; Myron Genel; Patricia Salber; Lewis Sandy; Louis M Sherwood; Stephen B Johnson; Veronica Catanese; Hugh Tilson; Kenneth Getz; Elaine L Larson; David Scheinberg; E Albert Reece; Harold Slavkin; Adrian Dobs; Jack Grebb; Rick A Martinez; Allan Korn; David Rimoin Journal: JAMA Date: 2003-03-12 Impact factor: 56.272
Authors: Ricardo V Cohen; Jose C Pinheiro; Carlos A Schiavon; João E Salles; Bernardo L Wajchenberg; David E Cummings Journal: Diabetes Care Date: 2012-07 Impact factor: 19.112
Authors: Alison M McDonald; Rosemary C Knight; Marion K Campbell; Vikki A Entwistle; Adrian M Grant; Jonathan A Cook; Diana R Elbourne; David Francis; Jo Garcia; Ian Roberts; Claire Snowdon Journal: Trials Date: 2006-04-07 Impact factor: 2.279
Authors: Sayeed Ikramuddin; Charles J Billington; Wei-Jei Lee; John P Bantle; Avis J Thomas; John E Connett; Daniel B Leslie; William B Inabnet; Robert W Jeffery; Keong Chong; Lee-Ming Chuang; Michael G Sarr; Michael D Jensen; Adrian Vella; Leaque Ahmed; Kumar Belani; Joyce L Schone; Amy E Olofson; Heather A Bainbridge; Patricia S Laqua; Qi Wang; Judith Korner Journal: Lancet Diabetes Endocrinol Date: 2015-05-12 Impact factor: 32.069
Authors: Sayeed Ikramuddin; Judith Korner; Wei-Jei Lee; Avis J Thomas; John E Connett; John P Bantle; Daniel B Leslie; Qi Wang; William B Inabnet; Robert W Jeffery; Keong Chong; Lee-Ming Chuang; Michael D Jensen; Adrian Vella; Leaque Ahmed; Kumar Belani; Charles J Billington Journal: JAMA Date: 2018-01-16 Impact factor: 56.272
Authors: Sayeed Ikramuddin; Judith Korner; Wei-Jei Lee; John P Bantle; Avis J Thomas; John E Connett; Daniel B Leslie; William B Inabnet; Qi Wang; Robert W Jeffery; Keong Chong; Lee-Ming Chuang; Michael D Jensen; Adrian Vella; Leaque Ahmed; Kumar Belani; Amy E Olofson; Heather A Bainbridge; Charles J Billington Journal: Diabetes Care Date: 2016-06-16 Impact factor: 19.112
Authors: Kim T Nguyen; Charles J Billington; Adrian Vella; Qi Wang; Leaque Ahmed; John P Bantle; Marc Bessler; John E Connett; William B Inabnet; Avis Thomas; Sayeed Ikramuddin; Judith Korner Journal: Diabetes Date: 2015-04-21 Impact factor: 9.461
Authors: Aruchuna Ruban; Christina Gabriele Prechtl; Michael Alan Glaysher; Navpreet Chhina; Werd Al-Najim; Alexander Dimitri Miras; Claire Smith; Anthony P Goldstone; Mayank Patel; Michael Moore; Hutan Ashrafian; James P Byrne; Julian P Teare Journal: BMJ Open Date: 2019-11-14 Impact factor: 2.692